1. Ludwig Institute for Cancer Research Limited (19 from 525 patents)

2. Cornell Research Foundation Inc. (9 from 1,521 patents)

3. Memorial Sloan Kettering Cancer Center (9 from 559 patents)

4. Other (6 from 832,843 patents)

5. The New York Hospital-cornell Medical Center (1 from 2 patents)

1. 8541202 - Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein

2. 8142786 - Method for inducing cell lysis with immunogenic portions of NY-ESO-1 protein

3. 8071717 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

4. 7888100 - Isolated nucleic acid molecules which encode immunogenic portions of NY-ESO-1 protein

5. 7795409 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per SE, and uses thereof

6. 7622568 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

7. 7354992 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

8. 7335467 - Breast cancer antigens

9. 7314721 - Small cell lung cancer associated antigens and uses therefor

10. 7132507 - Isolated cancer associated antigens NY-MEL 1 and NY-MEL 3, peptides based thereon, and their uses

11. 7115729 - Isolated nucleic acid molecules which encode peptides which bind to MHC class II molecules, such as HLA-DR53

12. 6911529 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

13. 6830924 - Isolated nucleic acid molecule encoding cancer associated antigens, the antigens per se, and uses thereof

14. 6774226 - Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof

15. 6723832 - Isolated peptides corresponding to amino acid sequences of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof